MRNA Quote, Financials, Valuation and Earnings

Biogen has a net margin of -117.16% compared to Moderna's net margin of 10.87%. Moderna's return on equity of -29.09% beat Biogen's return on equity of 10.33%.

Moderna has a consensus price target of $52.05, signalling upside risk potential of 95.16%. On the other hand Biogen has an analysts' consensus of $197.95 which suggests that it could grow by 74.59%. Given that Moderna has higher upside potential than Biogen, analysts believe Moderna is more attractive than Biogen.

Moderna has a beta of 2.231, which suggesting that the stock is 123.128% more volatile than S&P 500. In comparison Biogen has a beta of 0.057, suggesting its less volatile than the S&P 500 by 94.303%.

Moderna has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Moderna pays -- of its earnings as a dividend. Biogen pays out -- of its earnings as a dividend.

Moderna quarterly revenues are $956M, which are smaller than Biogen quarterly revenues of $2.5B. Moderna's net income of -$1.1B is lower than Biogen's net income of $266.7M. Notably, Moderna's price-to-earnings ratio is -- while Biogen's PE ratio is 10.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna is 3.23x versus 1.71x for Biogen. Usually stocks with elevated PS ratios are considered overvalued.

Gilead Sciences has a net margin of -117.16% compared to Moderna's net margin of 23.56%. Moderna's return on equity of -29.09% beat Gilead Sciences's return on equity of 2.5%.

Moderna has a consensus price target of $52.05, signalling upside risk potential of 95.16%. On the other hand Gilead Sciences has an analysts' consensus of $112.46 which suggests that it could grow by 10.91%. Given that Moderna has higher upside potential than Gilead Sciences, analysts believe Moderna is more attractive than Gilead Sciences.

Moderna has a beta of 2.231, which suggesting that the stock is 123.128% more volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.322, suggesting its less volatile than the S&P 500 by 67.831%.

Moderna has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences offers a yield of 3.06% to investors and pays a quarterly dividend of $0.79 per share. Moderna pays -- of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend.

Moderna quarterly revenues are $956M, which are smaller than Gilead Sciences quarterly revenues of $7.6B. Moderna's net income of -$1.1B is lower than Gilead Sciences's net income of $1.8B. Notably, Moderna's price-to-earnings ratio is -- while Gilead Sciences's PE ratio is 274.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna is 3.23x versus 4.44x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of -117.16% compared to Moderna's net margin of 24.16%. Moderna's return on equity of -29.09% beat Sarepta Therapeutics's return on equity of 20.83%.

Moderna has a consensus price target of $52.05, signalling upside risk potential of 95.16%. On the other hand Sarepta Therapeutics has an analysts' consensus of $159.96 which suggests that it could grow by 187.43%. Given that Sarepta Therapeutics has higher upside potential than Moderna, analysts believe Sarepta Therapeutics is more attractive than Moderna.

Moderna has a beta of 2.231, which suggesting that the stock is 123.128% more volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.930, suggesting its less volatile than the S&P 500 by 6.993%.

Moderna has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Moderna pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

Moderna quarterly revenues are $956M, which are larger than Sarepta Therapeutics quarterly revenues of $658.4M. Moderna's net income of -$1.1B is lower than Sarepta Therapeutics's net income of $159M. Notably, Moderna's price-to-earnings ratio is -- while Sarepta Therapeutics's PE ratio is 24.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna is 3.23x versus 3.26x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of -117.16% compared to Moderna's net margin of 31.35%. Moderna's return on equity of -29.09% beat Vertex Pharmaceuticals's return on equity of -3.23%.

Moderna has a consensus price target of $52.05, signalling upside risk potential of 95.16%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $497.94 which suggests that it could grow by 3.24%. Given that Moderna has higher upside potential than Vertex Pharmaceuticals, analysts believe Moderna is more attractive than Vertex Pharmaceuticals.

Moderna has a beta of 2.231, which suggesting that the stock is 123.128% more volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.504, suggesting its less volatile than the S&P 500 by 49.617%.

Moderna has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Moderna pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

Moderna quarterly revenues are $956M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.9B. Moderna's net income of -$1.1B is lower than Vertex Pharmaceuticals's net income of $913M. Notably, Moderna's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna is 3.23x versus 11.35x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.